Mauna Kea Technologie, biggest drop in the SRD market at mid-session on Friday July 22, 2022 – – 07/22/2022 at 12:32

(AOF) –

Mauna Kea Technologies

(-6.41% to 0.68 euros)

The title falls after the publication yesterday of sales down 13% in the second quarter of 2022.


An inevitable race for new blockbusters

The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.


Leave a Comment